Fundraising FoxBioqube Ventures — Full Portfolio
14 tracked investments · listed companies and verified rows first
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRA Capital+6 more
Anavo Therapeutics is a biopharmaceutical company using its IGNITE platform to develop phosphatase-targeted allosteric modulators, addressing drug targets previously considered undruggable.
BiotechHealthtechLeiden, NL
Birgit Zech(CEO)in
Co-investorsTaiho Ventures, LLCInkefM Ventures
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsJeito CapitalForbionBayern KapitalBioGeneration VenturesCanaan Partnerscoparion+2 more
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsHealthCapForbionGimvMedicxiRed Tree Venture
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Co-investorsAdvent Life SciencesBpifrancePureos BioventuresAdBio partners
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesInnovestor VenturesM VenturesSofinnova Partners4BIO Capital
Commit Biologics develops a complement-targeted drug discovery platform and antibody-based therapeutics for oncology, autoimmune diseases, and infectious disease indications.
BiotechHealthtechMedical DevicesAarhus, DK
Dennis(COO & Co-founder)Nick(Head of Discovery & Co-founder)Mikael(Head of Platform Technology & Co-founder)Heidi(Head of Drug Screening & Co-founder)Thomas(CEO)
Co-investorsKorysNovo Holdings
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsEQT Life SciencesFund+JDRF T1D Fund
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Co-investorsBioBritBioRock VenturesSamsara BioCapitalOberland CapitalPolaris Partners
S-Biomedic develops microbiome-based skincare products designed to restore the skin's healthy microbial balance for people with certain skin conditions.
BiotechHealthtechWellness & Fitness
Bernhard Päetzold(Co-founder)inMarc Güell(Co-founder)inVeronika Oudova(Co-founder)in
Co-investorsBeiersdorf Innovation FundVerve Ventures
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Anavo TherapeuticsCalypso BiotechEnhanc3D GenomicsSyndesi Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.